Guidance
Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs)
Based on current timelines, PCV13 4-dose vials have become available to Gavi countries in 2017 and PCV10 4-dose vials are forecasted to become available in 2018. The availability of PCV10 4-dose vials is pending its prequalification by the World Health Organization, expected in late 2017, and, as the case may be, its local registration. These FAQs give an overview of the characteristics of these two new PCV 4-dose vial presentations, as well as the process of switching presentations and the support provided by Gavi in doing so. If you are interested in switching from your current PCV presentation to one of these new presentations, you will need to submit a request through the Gavi country portal during the annual reporting cycle in May 2017, or if urgent, through a letter to Gavi.
Authors
Languages
- English
Publication year
2017
Publisher
Gavi
Type
Guidance
Categories
- Vaccines & delivery devices
Diseases
- Pneumococcal disease
Topic references
EPI-CORE-PNEUMO
Title | Author | Year | Type | Language |
---|---|---|---|---|
Characteristics of different presentations of Pneumococcal Conjugate Vaccines | World Health Organization (WHO) | 2017 | Poster/infographic | English |
Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs) | Gavi, the Vaccine Alliance | 2017 | Guidance | English |
Pneumococcal Vaccine: Handling the change in product manufacturer and presentation | World Health Organization (WHO) | 2017 | Guidance | Portuguese |